-
公开(公告)号：US08618131B2
公开(公告)日：2013-12-31
申请号：US13545523
申请日：2012-07-10
IPC分类号： A61K31/47 , C07D215/00
CPC分类号： C07D211/46 , A61K31/445 , A61K31/452 , C07D211/48 , C07D211/58 , C07D401/06 , C07D401/12 , C07D401/14 , C07D405/12 , C07D409/06 , C07D409/12 , C07D453/02 , C07D471/08 , G01N33/9433
摘要： This invention provides biphenyl derivatives of formula I: wherein R1, R2, R3, R4, R5, R6, R7, W, a, b and c are as defined in the specification, or a pharmaceutically acceptable salt or solvate or stereoisomer thereof. The biphenyl derivatives of this invention possess both β2 adrenergic receptor agonist and muscarinic receptor antagonist activity and therefore, such biphenyl derivatives are useful for treating pulmonary disorders, such as chronic obstructive pulmonary disease and asthmas.
摘要翻译： 本发明提供式I的联苯衍生物：其中R1，R2，R3，R4，R5，R6，R7，W，a，b和c如说明书中所定义，或其药学上可接受的盐或溶剂合物或立体异构体。 本发明的联苯衍生物具有β2肾上腺素能受体激动剂和毒蕈碱受体拮抗剂活性，因此，这种联苯衍生物可用于治疗肺部疾病，如慢性阻塞性肺病和哮喘。
-
公开(公告)号：US08501398B2
公开(公告)日：2013-08-06
申请号：US12373075
申请日：2007-07-11
申请人： David Parker , Robert Anthony Poole , Filip Kielar
发明人： David Parker , Robert Anthony Poole , Filip Kielar
CPC分类号： G01N33/542 , G01N33/62 , G01N33/6812 , G01N33/9413 , G01N33/942 , G01N33/9433 , Y10T436/203332
摘要： The invention provides a method of determining the amount of an analyte having an oxidation potential, for a one electron oxidation process, of about +0.10 to about +1.20 volts at pH 7, relative to the normal hydrogen electrode at 298K, said method comprising measuring the emission intensity or emission lifetime, at two or more wavelengths, from a sample comprising said analyte and two or more different macrocyclic lanthanide (III) complexes, wherein each of said macrocyclic lanthanide (III) complexes comprises a different lanthanide ion but the same macrocyclic ligand, and using a ratio of emission intensities or emission lifetimes measured at two different wavelengths to calculate the amount of analyte in said sample.
摘要翻译： 本发明提供了一种在298K下相对于正常氢电极测定在pH7下约+0.10至约+ 1.20伏的电子氧化过程的具有氧化电位的分析物的量的方法，所述方法包括测量 来自包含所述分析物的样品和两种或更多种不同的大环镧系元素（III）络合物的两个或更多个波长的发射强度或发射寿命，其中每个所述大环镧系元素（III）络合物包含不同的镧系元素离子但是相同的大环 并且使用在两个不同波长处测量的发射强度或发射寿命的比率来计算所述样品中的分析物的量。
-
公开(公告)号：US07879879B2
公开(公告)日：2011-02-01
申请号：US11448317
申请日：2006-06-07
申请人： Mathai Mammen , Sarah Dunham , Adam Hughes , Craig Husfeld , Eric Stangeland , Yan Chen
发明人： Mathai Mammen , Sarah Dunham , Adam Hughes , Craig Husfeld , Eric Stangeland , Yan Chen
IPC分类号： A61K31/445 , C07D211/54 , C07D211/56
CPC分类号： C07D211/46 , A61K31/445 , A61K31/452 , C07D211/48 , C07D211/58 , C07D401/06 , C07D401/12 , C07D401/14 , C07D405/12 , C07D409/06 , C07D409/12 , C07D453/02 , C07D471/08 , G01N33/9433
摘要： This invention provides biphenyl derivatives of formula I: wherein R1, R2, R3, R4, R5, R6, R7, W, a, b and c are as defined in the specification, or a pharmaceutically acceptable salt or solvate or stereoisomer thereof. The biphenyl derivatives of this invention possess both β2 adrenergic receptor agonist and muscarinic receptor antagonist activity and therefore, such biphenyl derivatives are useful for treating pulmonary disorders, such as chronic obstructive pulmonary disease and asthma.
摘要翻译： 本发明提供式I的联苯衍生物：其中R1，R2，R3，R4，R5，R6，R7，W，a，b和c如说明书中所定义，或其药学上可接受的盐或溶剂合物或立体异构体。 本发明的联苯衍生物具有二肾上腺素能受体激动剂和毒蕈碱受体拮抗剂活性，因此，这种联苯衍生物可用于治疗肺部疾病，如慢性阻塞性肺疾病和哮喘。
-
公开(公告)号：US07829545B2
公开(公告)日：2010-11-09
申请号：US10268969
申请日：2002-10-11
申请人： Debra A. Schwinn
发明人： Debra A. Schwinn
CPC分类号： G01N33/9433 , C07K14/70571 , C12Q1/6883 , G01N2500/04 , G01N2800/34
摘要： The present invention relates to bladder and lower urinary tract syndromes, particularly, irrative symptoms, and to a method of treating same using α1d-adrenergic receptor (α1dAR) antagonists. The invention further relates to a method of screening compounds for their ability to serve as α1dAR selective antagonists.
摘要翻译： 本发明涉及膀胱和下尿路症状特别是刺激性症状，以及使用α1d-肾上腺素能受体（α1dAR）拮抗剂治疗膀胱和下尿路症状的方法。 本发明还涉及一种筛选化合物作为α1dAR选择性拮抗剂的能力的方法。
-
公开(公告)号：US07355046B2
公开(公告)日：2008-04-08
申请号：US11448294
申请日：2006-06-07
申请人： Mathai Mammen , Adam Hughes , Yan Chen
发明人： Mathai Mammen , Adam Hughes , Yan Chen
IPC分类号： C07D221/02
CPC分类号： C07D211/46 , A61K31/445 , A61K31/452 , C07D211/48 , C07D211/58 , C07D401/06 , C07D401/12 , C07D401/14 , C07D405/12 , C07D409/06 , C07D409/12 , C07D453/02 , C07D471/08 , G01N33/9433
摘要： This invention provides biphenyl derivatives of formula I: wherein R1, R2, R3, R4, R5, R6, R7, W, a, b and c are as defined in the specification, or a pharmaceutically acceptable salt or solvate or stereoisomer thereof. The biphenyl derivatives of this invention possess both β2 adrenergic receptor agonist and muscarinic receptor antagonist activity and therefore, such biphenyl derivatives are useful for treating pulmonary disorders, such as chronic obstructive pulmonary disease and asthma.
摘要翻译： 本发明提供式I的联苯衍生物：其中R 1，R 2，R 3，R 4， R 5，R 6，R 7，W，a，b和c如本说明书中所定义，或其药学上可接受的盐或 其溶剂合物或立体异构体。 本发明的联苯衍生物具有β2N2肾上腺素能受体激动剂和毒蕈碱受体拮抗剂活性，因此，这种联苯衍生物可用于治疗肺部疾病，如慢性阻塞性肺病和哮喘。
-
公开(公告)号：US07345175B2
公开(公告)日：2008-03-18
申请号：US11448293
申请日：2006-06-07
申请人： Mathai Mammen , Adam Hughes , Yan Chen
发明人： Mathai Mammen , Adam Hughes , Yan Chen
IPC分类号： C07D211/00
CPC分类号： C07D211/46 , A61K31/445 , A61K31/452 , C07D211/48 , C07D211/58 , C07D401/06 , C07D401/12 , C07D401/14 , C07D405/12 , C07D409/06 , C07D409/12 , C07D453/02 , C07D471/08 , G01N33/9433
摘要： This invention provides biphenyl derivatives of formula I: wherein R1, R2, R3, R4, R5, R6, R7, W, a, b and c are as defined in the specification, or a pharmaceutically acceptable salt or solvate or stereoisomer thereof. The biphenyl derivatives of this invention possess both β2 adrenergic receptor agonist and muscarinic receptor antagonist activity and therefore, such biphenyl derivatives are useful for treating pulmonary disorders, such as chronic obstructive pulmonary disease and asthma.
-
公开(公告)号：US20070088054A1
公开(公告)日：2007-04-19
申请号：US11604607
申请日：2006-11-27
申请人： Mathai Mammen , Adam Hughes , Eric Stangeland , Yan Chen
发明人： Mathai Mammen , Adam Hughes , Eric Stangeland , Yan Chen
IPC分类号： C07D211/54 , C07D211/06 , A61K31/445
CPC分类号： C07D211/46 , A61K31/445 , A61K31/452 , C07D211/48 , C07D211/58 , C07D401/06 , C07D401/12 , C07D401/14 , C07D405/12 , C07D409/06 , C07D409/12 , C07D453/02 , C07D471/08 , G01N33/9433
摘要： This invention provides biphenyl derivatives of formula I: wherein R1, R2, R3, R4, R5, R6, R7, W, a, b and c are as defined in the specification, or a pharmaceutically acceptable salt or solvate or stereoisomer thereof. The biphenyl derivatives of this invention possess both β2 adrenergic receptor agonist and muscarinic receptor antagonist activity and therefore, such biphenyl derivatives are useful for treating pulmonary disorders, such as chronic obstructive pulmonary disease and asthma.
-
公开(公告)号：US20030134812A1
公开(公告)日：2003-07-17
申请号：US10268969
申请日：2002-10-11
申请人： DUKE UNIVERSITY
发明人： Debra A. Schwinn
IPC分类号： A61K048/00 , C12Q001/68
CPC分类号： G01N33/9433 , C07K14/70571 , C12Q1/6883 , G01N2500/04 , G01N2800/34
摘要： The present invention relates to bladder and lower urinary tract syndromes, particularly, irrative symptoms, and to a method of treating same using null1d-adrenergic receptor (null1dAR) antagonists. The invention further relates to a method of screening compounds for their ability to serve as null1dAR selective antagonists.
摘要翻译： 本发明涉及膀胱和下尿路综合征，特别是刺激性症状，以及使用α1-肾上腺素能受体（α1dAR）拮抗剂治疗相同方法。 本发明还涉及一种筛选化合物作为α1dAR选择性拮抗剂的能力的方法。
-
公开(公告)号：US20030113771A1
公开(公告)日：2003-06-19
申请号：US10238129
申请日：2002-09-10
IPC分类号： C12Q001/68 , C07H021/04 , C12P021/02 , C12N005/06 , C07K014/705
CPC分类号： C12Q1/6876 , A01K2207/15 , A01K2217/00 , A01K2217/05 , A01K2217/075 , A01K2227/10 , A01K2227/105 , A01K2267/02 , A01K2267/03 , A01K2267/0393 , A61K38/00 , C07K14/70571 , C12N15/85 , C12N15/8509 , C12Q1/6897 , C12Q2600/158 , G01N33/9433 , G01N2500/10
摘要： This invention provides an isolated nucleic acid, vectors, transformed mammalian cells and non-human transgenic animals that encode and express normal or mutant alpha 1a, alpha 1b and alpha 1c adrenergic receptor genes. This invention also provides a protein, and an antibody directed to the protein and pharmaceutical compounds related to alpha 1a, alpha 1b and alpha 1c adrenergic receptors. This invention provides nucleic acid probes, and antisense oligonucleotides complementary to alpha 1a, alpha 1b and alpha 1c adrenergic receptor genes. This invention further provides methods for determining ligand binding, detecting expression, drug screening, and treatments for alleviating abnormalities associated with human alpha 1a, alpha 1b and alpha 1c adrenergic receptors.
-
公开(公告)号：US6083705A
公开(公告)日：2000-07-04
申请号：US206899
申请日：1998-12-07
IPC分类号： A01K67/027 , A61K38/00 , A61K39/395 , A61K45/00 , A61P3/08 , A61P9/06 , A61P9/08 , A61P9/10 , A61P9/12 , A61P13/02 , A61P15/00 , A61P27/02 , A61P27/16 , A61P43/00 , C07H21/04 , C07K14/705 , C07K14/72 , C07K16/28 , C12N5/06 , C12N15/09 , C12N15/12 , C12N15/85 , C12P21/02 , C12P21/08 , C12Q1/02 , C12Q1/68 , G01N33/53 , G01N33/577 , G01N33/94
CPC分类号： C12Q1/6876 , C07K14/70571 , C12N15/85 , C12N15/8509 , C12Q1/6897 , G01N33/9433 , A01K2207/15 , A01K2217/00 , A01K2217/05 , A01K2217/075 , A01K2227/10 , A01K2227/105 , A01K2267/02 , A01K2267/03 , A01K2267/0393 , A61K38/00 , C12Q2600/158 , G01N2500/10
摘要： This invention provides an isolated nucleic acid, vectors, transformed mammalian cells and non-human transgenic animals that encode and express normal or mutant .alpha. 1a, .alpha. 1b and .alpha. 1c adrenergic receptor genes. This invention also provides a protein, and an antibody directed to the protein and pharmaceutical compounds related to .alpha. 1a, .alpha. 1b and .alpha. 1c adrenergic receptors. This invention provides nucleic acid probes, and antisense oligonucleotides complementary to .alpha. 1a, .alpha. 1b and .alpha. 1c adrenergic receptor genes. This invention further provides methods for determining ligand binding, detecting expression, drug screening, and treatments for alleviating abnormalities associated with human .alpha. 1a, .alpha. 1b and .alpha. 1c adrenergic receptors.
-
-
-
-
-
-
-
-
-
搜索结果
72 条记录 (耗时 0.056 秒)